ArticleSurgical endoscopy2026
Risk of bleeding after esophagogastroduodenoscopy with mucosal resection in patients with cirrhosis.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Outcomes of GLP-1 Therapy vs. Bariatric Surgery in Patients with Cirrhosis.Obesity surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEsophagogastroduodenoscopy (EGD) with endoscopic mucosal resection (EMR) is commonly used for evaluating and managing gastrointestinal lesions. This study aimed to assess the 30-day risk of bleeding and other adverse outcomes following EGD-EMR in cirrhotic patients.
methodsThis retrospective cohort study utilized data from the US Collaborative Network to evaluate bleeding risk following EGD-EMR in cirrhotic patients. One-to-one propensity score matching was performed, with the primary outcome being bleeding within 30 days post-procedure.
resultsEach cohort included 1,045 patients. Cirrhotic patients had higher risk of post-EGD-EMR bleeding (OR 1.65, 95% CI 1.21-2.25, P = 0.002) and were more likely to require a blood transfusion (OR 2.54, 95% CI 1.21-5.31, P = 0.011). However, ICU admissions (OR 1.33, P = 0.29) and endoscopic reinterventions (OR 1.31, P = 0.25) did not differ significantly. Patients with decompensated cirrhosis had a higher bleeding risk compared to controls (OR 1.62, 95% CI 1.05-2.51, P = 0.03), while those with compensated cirrhosis showed no increased risk (OR 1.16, P = 0.55). DISCUSSION: This study found increased post-procedural bleeding in cirrhotic patients, particularly those with decompensated cirrhosis. Careful pre-procedural management of coagulopathy is crucial to minimize complications in these patients.
Indexed as
Identifiers
41295997What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.